基质金属蛋白酶及其抑制物与原发性高血压

被引：5

作者：

李超民

拓步雄

机构：

[1] 西安市解放军第中心医院心内科

来源：

中华高血压杂志 | 2008年 / 16卷 / 09期

关键词：

基质金属蛋白酶; MMPS; 高血压心脏病; MMPs; 高血压性心力衰竭; MMPI; TIMP; 高血压患者; 他汀类降脂药; 单纯收缩期高血压; 抑制物;

D O I：

10.16439/j.cnki.1673-7245.2008.09.005

中图分类号：

R544.1 [高血压];

学科分类号：

1002 ; 100201 ;

摘要：

<正> 基质金属蛋白酶(matrix metalloproteinase,MMPs)是参与降解全身各种组织细胞外基质(extra-cellular matrix,ECM)的蛋白酶家族,参与正常和病理条件下的组织重构。组织金属蛋白酶抑制物(TIMP)是 MMPs 的特异性抑制物。近年来随着对 MMPs/

引用

页码：779 / 781

页数：3

共 11 条

[1] Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats [J].

Gianella, Anita ;

Nobili, Elena ;

Abbate, Mauro ;

Zoja, Carla ;

Gelosa, Paolo ;

Mussoni, Luciana ;

Bellosta, Stefano ;

Canavesi, Monica ;

Rottoli, Daniela ;

Guerrini, Uliano ;

Brioschi, Maura ;

Banfi, Cristina ;

Tremoli, Elena ;

Remuzzi, Giuseppe ;

Sironi, Luigi .

AMERICAN JOURNAL OF PATHOLOGY, 2007, 170 (04) :1165-1177

[2] Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure [J].

Saka, Masako ;

Obata, Koji ;

Ichihara, Sahoko ;

Cheng, Xian Wu ;

Kimata, Hirotaka ;

Nishizawa, Takao ;

Noda, Akiko ;

Izawa, Hideo ;

Nagata, Kohzo ;

Murohara, Toyoaki ;

Yokota, Mitsuhiro .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 47 (06) :770-779

[3]

Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease[J] . S Hinan Ahmed,Leslie L. Clark,Weems R. Pennington,Carson S. Webb,D Dirk Bonnema,Amy H. Leonardi,Catherine D. McClure,Francis G. Spinale,Michael R. Zile.Circulation . 2006 (17)

[4] Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload [J].

Matsusaka, H ;

Ide, T ;

Matsushima, S ;

Ikeuchi, M ;

Kubota, T ;

Sunagawa, K ;

Kinugawa, S ;

Tsutsui, H .

HYPERTENSION, 2006, 47 (04) :711-717

[5]

Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade[J] . James P Spiers,Elizabeth J Kelso,Wei F Siah,Gillian Edge,Guojie Song,Barbara J McDermott,Martina Hennessy.Journal of Hypertension . 2005 (9)

[6] Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition [J].

Bouvet, C ;

Gilbert, LA ;

Girardot, D ;

deBlois, D ;

Moreau, P .

HYPERTENSION, 2005, 45 (03) :432-437

[7] Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients [J].

Ergul, A ;

Portik-Dobos, V ;

Hutchinson, J ;

Franco, J ;

Anstadt, MP .

AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (09) :775-782

[8]

Activation of Matrix Metalloproteinases Precedes Left Ventricular Remodeling in Hypertensive Heart Failure Rats: Its Inhibition as a Primary Effect of Angiotensin-Converting Enzyme Inhibitor[J] . Yasushi Sakata,Kazuhiro Yamamoto,Toshiaki Mano,Nagahiro Nishikawa,Junichi Yoshida,Masatsugu Hori,Takeshi Miwa,Tohru Masuyama.Circulation: Journal of the American Heart Association . 2004 (17)

[9] Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling [J].

Lehoux, S ;

Lemarié, CA ;

Esposito, B ;

Lijnen, HR ;

Tedgui, A .

CIRCULATION, 2004, 109 (08) :1041-1047

[10]

Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension?[J] . Muzahir H Tayebjee,Robert J MacFadyen,Gregory YH Lip.Journal of Hypertension . 2003 (12)

← 1 2 →